Sweden
· Delayed Price · Currency is SEK Egetis Therapeutics AB Statistics
Total Valuation
Egetis Therapeutics AB has a market cap or net worth of SEK 1.70 billion. The enterprise value is 1.61 billion.
| Market Cap | 1.70B |
| Enterprise Value | 1.61B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Egetis Therapeutics AB has 292.57 million shares outstanding. The number of shares has increased by 2.25% in one year.
| Shares Outstanding | 292.57M |
| Shares Change (YoY) | +2.25% |
| Shares Change (QoQ) | +18.92% |
| Owned by Insiders (%) | 17.60% |
| Owned by Institutions (%) | 24.56% |
| Float | 140.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 23.00 |
| PB Ratio | 4.23 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.06 |
| EV / Sales | 22.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.56, with a Debt / Equity ratio of 27.52.
| Current Ratio | 1.56 |
| Quick Ratio | 1.52 |
| Debt / Equity | 27.52 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22.05 |
Financial Efficiency
Return on equity (ROE) is -67.07% and return on invested capital (ROIC) is -36.19%.
| Return on Equity (ROE) | -67.07% |
| Return on Assets (ROA) | -30.74% |
| Return on Capital (ROIC) | -36.19% |
| Revenue Per Employee | 2.08M |
| Profits Per Employee | -9.39M |
| Employee Count | 34 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 375.45 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +23.40% in the last 52 weeks. The beta is 1.44, so Egetis Therapeutics AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.44 |
| 52-Week Price Change | +23.40% |
| 50-Day Moving Average | 5.55 |
| 200-Day Moving Average | 6.11 |
| Relative Strength Index (RSI) | 50.58 |
| Average Volume (20 Days) | 433,113 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Egetis Therapeutics AB had revenue of SEK 70.80 million and -319.40 million in losses. Loss per share was -1.20.
| Revenue | 70.80M |
| Gross Profit | -135.70M |
| Operating Income | -308.70M |
| Pretax Income | -319.30M |
| Net Income | -319.40M |
| EBITDA | -305.10M |
| EBIT | -308.70M |
| Loss Per Share | -1.20 |
Balance Sheet
The company has 192.60 million in cash and 110.50 million in debt, giving a net cash position of 82.10 million or 0.28 per share.
| Cash & Cash Equivalents | 192.60M |
| Total Debt | 110.50M |
| Net Cash | 82.10M |
| Net Cash Per Share | 0.28 |
| Equity (Book Value) | 401.50M |
| Book Value Per Share | 1.37 |
| Working Capital | 83.30M |
Cash Flow
| Operating Cash Flow | -246.60M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | -191.67% |
| Operating Margin | -436.02% |
| Pretax Margin | -450.99% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Egetis Therapeutics AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.25% |
| Shareholder Yield | -2.25% |
| Earnings Yield | -20.74% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |